...
首页> 外文期刊>Clinical Endocrinology >Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone
【24h】

Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone

机译:CYP21A2基因在17-羟孕酮短暂升高患儿新生儿干血斑中的遗传分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background Neonatal screening for congenital adrenal hyperplasia (CAH) identifies a certain proportion of newborns with transient moderate elevation of 17-hydroxyprogesterone (17-OHP). These children require regular follow-up until normalization of their 17-OHP levels. We investigated the possibility of reducing the individuals' recall rates by using genetic methods on their original neonatal dried blood spots. Patients and Methods We analysed neonatal dried blood spots from 753 subjects with transiently elevated levels of 17-OHP. The CYP21A2 gene was sequenced to detect point mutations, and the presence of CYP21A2 was further confirmed by two methods utilizing the difference between CYP21A2 and its CYP21A1P pseudogene in the sequence of exon 3 (8-bp deletion). The accuracy of the methods was verified using samples from 70 subjects with known CYP21A2 mutations and 181 healthy children. Result Among the 701 successfully sequenced samples from subjects with transiently elevated 17-OHP, 670 (95%) had no point mutations or novel variants in the CYP21A2 gene. We found no individuals carrying genotypes consistent with the diagnosis of CAH (i.e. homozygotes or compound heterozygotes for point mutations, large deletions or rearrangements). However, 21 heterozygous carriers of known point mutations that cause the classic and nonclassic forms of CAH were identified. Additionally, we detected eight heterozygous and two homozygous point variants with unknown functional significance. Conclusion Although CAH caused by 21-hydroxylase deficiency could be genetically excluded with a reasonable degree of confidence in 95% of the genotyped subjects that had transiently elevated 17-OHP, the performance of the tests was suboptimal when performed using dried blood spots and time-consuming in comparison with the current practice of repeated measurements of 17-OHP. The introduction of this method into clinical practice seems to be impractical at this stage.
机译:背景技术新生儿筛查先天性肾上腺皮质增生(CAH)可确定一定比例的17-羟孕酮(17-OHP)短暂升高的新生儿。这些孩子需要定期随访,直到其17-OHP水平恢复正常。我们调查了通过使用遗传方法在其原始的新生儿干血斑上降低个体的召回率的可能性。患者和方法我们分析了753名受试者的新生儿干血斑,这些受试者的17-OHP水平暂时升高。对CYP21A2基因进行测序以检测点突变,并利用两种方法利用CYP21A2与其CYP21A1P假基因在外显子3(缺失8-bp)中的差异进一步证实了CYP21A2的存在。使用来自70个已知CYP21A2突变受试者和181名健康儿童的样本验证了方法的准确性。结果在来自瞬时升高17-OHP的对象的701个成功测序的样本中,有670个(95%)在CYP21A2基因中没有点突变或新变异。我们发现没有携带与CAH诊断相符的基因型的个体(即纯合子或复合杂合子用于点突变,大缺失或重排)。但是,鉴定出21种已知点突变的杂合子载体,这些突变导致经典和非经典形式的CAH。此外,我们检测到八个杂合点和两个纯合点变体,其功能意义未知。结论虽然在21%的基因型受试者中17-OHP短暂升高,可以合理地排除21-羟化酶缺乏症引起的CAH,但使用干血斑和时间间隔进行的测试表现欠佳。与目前重复测量17-OHP的做法相比,其消耗更大。在此阶段将这种方法引入临床实践似乎是不切实际的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号